|1.||Ando, Tsuyoshi: 4 articles (01/2005 - 10/2002)|
|2.||Takagi, Norio: 4 articles (01/2005 - 10/2002)|
|3.||Takeo, Satoshi: 4 articles (01/2005 - 10/2002)|
|4.||Shiotani, T: 4 articles (10/2000 - 01/2000)|
|5.||Sakurada, Shinobu: 3 articles (10/2005 - 06/2005)|
|6.||Takazawa, Akira: 3 articles (10/2005 - 06/2005)|
|7.||Kitano, Yutaka: 3 articles (10/2005 - 06/2005)|
|8.||Takasuna, Kiyoshi: 3 articles (10/2005 - 06/2005)|
|9.||Komiyama, Chika: 3 articles (10/2005 - 06/2005)|
|10.||Makino, Mitsuhiro: 3 articles (10/2005 - 06/2005)|
01/01/1992 - "Thus pretreatment with DM-9384 exerted minor protective effects on the alterations induced in monoamine systems by transient forebrain ischemia."
05/01/2001 - "Recent studies have shown that nefiracetam ameliorates cognitive dysfunction because of ischemia when behavioral testing occurs during treatment. "
01/01/1992 - "Effects of DM-9384, a pyrrolidone derivative, on ischemia-induced changes in the central monoamine systems."
02/01/2003 - "The present study suggests that nefiracetam may have an ability to cause persistent improvement of learning and memory function, possibly through protection against the ischemia-induced impairment to the adenylyl cyclase/cAMP/PKA signal transduction pathway."
01/01/2008 - "In preliminary trials, nefiracetam, a gamma aminobutyric compound, enhanced blood flow and improved mood following stroke. "
01/01/2009 - "Nefiracetam is a novel pyrrolidone-type nootropic compound shown in preliminary trials to increase blood flow and improve patient outlook and energy following stroke. "
01/01/2008 - "Within 3 months following stroke with major depression, 159 patients were enrolled in a double-blind trial of nefiracetam or placebo. "
01/01/2009 - "Of 137 stroke patients with major depression, 70 also met published diagnostic criteria for apathy (51.1%) and were randomly assigned either to placebo or 600 mg or 900 mg of nefiracetam per day, and received at least 4 weeks of treatment. "
05/01/2002 - "By September 1999, nefiracetam was In phase II trials in the US for the treatment of mental symptoms associated with sequelae of stroke and Alzheimer's type dementia. "
|3.||Alzheimer Disease (Alzheimer's Disease)
01/01/1999 - "7. These results suggest that nefiracetam may be useful for the treatment of patients with Alzheimer's disease."
02/07/1997 - "Because of the parallels between conditioning in rabbits with disrupted hippocampal cholinergic systems and conditioning in Alzheimer's disease (AD), these results suggest that nefiracetam may ameliorate conditioning in AD as it ameliorates conditioning in older rabbits."
04/01/2002 - "The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). "
08/14/2000 - "The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease."
05/01/1997 - "Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD). "
|4.||Amnesia (Dissociative Amnesia)
02/01/1997 - "Effects of nefiracetam on amnesia animal models with neuronal dysfunctions."
01/01/1992 - "These results suggest that DM-9384 attenuates CXM-induced amnesia by interacting with AChergic neuronal system and enhancing protein synthesis in the brain."
01/01/1992 - "Pre-training administration of DM-9384 attenuated the CXM-induced amnesia as indicated by prolongation of step-down latency. "
04/01/1991 - "These results suggest that DM-9384 attenuates CXM-induced amnesia by interacting with GA-BAergic and AChergic neuronal systems and enhancing protein synthesis in the brain."
04/01/1991 - "Pre- and post-training and pre-retention test administration of DM-9384 attenuated the CXM-induced amnesia as indicated by prolongation of step-down latency. "
|5.||Memory Disorders (Memory Loss)
01/01/1999 - "4. Nefiracetam, at a dose range of 1-10 mg kg(-1), improved learning and memory deficits in the A beta-(1-42)-infused rats when it was administered p.o. "
10/01/2002 - "Nootropic drug nefiracetam and related compounds are used in diseases with learning and memory deficits. "
07/01/1993 - "Co-administration of nefiracetam with scopolamine was not necessary to achieve the antiamnesic action, as nefiracetam given during training significantly improved the memory deficits produced by scopolamine at the 6-h posttraining time. "
01/01/1999 - "2. In the present study, we investigated the effects of nefiracetam [N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide, DM-9384] on A beta-(1-42)-induced learning and memory deficits in rats. "
|5.||Brain-Derived Neurotrophic Factor (BDNF)
|6.||Adenylate Cyclase (Adenylyl Cyclase)
|7.||Synapsins (Synapsin I)